ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, June 30, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ADMA Biologics, Inc. (“ADMA” or “the Company”) (
NASDAQ: ADMA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
ADMA Biologics (NASDAQ: ADMA) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a top complex litigation law firm, is investigating ADMA Biologics (
NASDAQ: ADMA) (“ADMA Biologics” or the “Company”) for potential violations of the federal securities laws.
ADMA BIOLOGICS, INC. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates ADMA Biologics, Inc.’s Directors and Officers for Breach of Fiduciary Duties – ADMAScott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of ADMA Biologics, Inc. (
NASDAQ: ADMA) failed to manage ADMA Biologics in an acceptable manner, breaching their fiduciary duties to ADMA Biologics, and whether ADMA Biologics and its shareholders have suffered damages as a result. Attorney Joseph A. Pettigrew is heading the investigation—what shareholders need to know:
ADMA SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of ADMA Biologics, Inc. Investors - Contact Kirby McInerney LLP by August 10, 2026NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased ADMA Biologics, Inc. (“ADMA” or the “Company”) (
NASDAQ:ADMA) securities to contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost.
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, June 26, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ADMA Biologics, Inc. (“ADMA” or “the Company”) (
NASDAQ: ADMA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
ADMA Biologics, Inc. (ADMA) Investors: August 10, 2026, Deadline in Securities Fraud Class Action LawsuitSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against ADMA Biologics, Inc. and Encourages Investors to Contact the FirmBragar Eagel & Squire, P.C. Litigation Partners Brandon Walker and Melissa Fortunato Encourage Investors Who Suffered Losses In ADMA To Contact Them Directly To Discuss Their Options
ADMA Biologics, Inc. (ADMA) Securities Fraud Class Action Lawsuit Filed; August 10, 2026, Lead Plaintiff DeadlineSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ADMA Biologics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ADMA Biologics, Inc. - ADMANEW ORLEANS, June 25, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 10, 2026 to file lead plaintiff applications in a securities class action lawsuit against ADMA Biologics, Inc. (NasdaqGM: ADMA) (“ADMA” or the “Company”), if they purchased or otherwise acquired the Company’s securities between August 9, 2024 and March 25, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
ADMA BIOLOGICS, INC. (ADMA) INVESTOR ALERT Investors With Large Losses in ADMA Biologics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their RightsNEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of ADMA Biologics, Inc. (“ADMA” or the “Company”) (
NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, inclusive.What To Do Next:
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application DeadlineNEW YORK and NEW ORLEANS, June 23, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. (“ADMA” or the “Company”) (NasdaqGM: ADMA) of a class action securities lawsuit.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ADMA Biologics, Inc. of Class Action Lawsuit and Upcoming Deadlines – ADMANEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against ADMA Biologics, Inc. (“ADMA” or the “Company”) (
NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
